Pictet Asset Management
DYN icon

Pictet Asset Management’s Dyne Therapeutics DYN Stock Holding History

Pictet Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$351K Buy
19,372
+6,409
+49% +$111K ﹤0.01% 1646
2025
Q4 		$254K Buy
+12,963
New +$245K ﹤0.01% 1796
2025
Q1 		– Sell
-323,552
Closed -$7.62M – 2032
2024
Q4 		$7.62M Buy
323,552
+18,847
+6% +$557K 0.01% 731
2024
Q3 		$10.3M Buy
304,705
+9,957
+3% +$396K 0.01% 645
2024
Q2 		$10.4M Buy
+294,748
New +$8.56M 0.01% 616

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Pictet Asset Management's DYN Position: Q1 2026 in Review

Pictet Asset Management increased its Dyne Therapeutics (DYN) stake by 49% in Q1 2026, buying an estimated $111K and bringing the position to 19,372 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #1646.

Pictet Asset Management first reported a position in DYN in Q2 2024 and has held it in 5 quarters since. The position peaked at $10.4M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Pictet Asset Management held 19,372 shares of Dyne Therapeutics worth $351K as of Q1 2026.
  • Pictet Asset Management bought 6,409 Dyne Therapeutics shares in Q1 2026, an estimated $111K.
  • Dyne Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #1646 holding.
  • Pictet Asset Management first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Pictet Asset Management's Dyne Therapeutics position peaked at $10.4M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.